Clinical trials
Muscle Invasive Bladder Cancer (MIBC) clinical trials
Below are recruiting muscle invasive bladder cancer (mibc) clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Birmingham, AlabamaAges 18 years+ - NCT07726602Recruiting
Tumor DNA blood test for muscle-invasive bladder cancer
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
Portland, OregonAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT07750470Recruiting
Pet scan to guide treatment for muscle-invasive bladder cancer
This study uses a special PET/CT scan to see how far your bladder cancer has spread. The results may help doctors plan the best treatment for you.
FerraraAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT06290687RecruitingPhase 2
Partial cystectomy with chemo for bladder cancer
This trial tests whether removing part of the bladder (partial cystectomy) along with standard chemotherapy or immunotherapy before surgery is effective for people with a specific type of bladder cancer that hasn't spread beyond the bladder.
Cleveland, OhioAges 19 years+ - NCT04724928RecruitingPhase 2
PET-CT scan to guide bladder cancer treatment decisions
This Phase 2 study checks whether an FDG PET-CT scan can help doctors better predict bladder cancer risk and adjust treatment. You may still get standard bladder cancer care, but the study uses the scan results to help decide how aggressive treatment should be.
GhentAges 18 years+ - NCT06879145RecruitingPhase 2/Phase 3
Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05833867RecruitingPhase 1
Bladder cancer trial combining radiation and Sacituzumab
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
Cleveland, OhioAges 18 years+ - NCT07296705RecruitingPhase 2
New drug combo to save the bladder in HER2-positive bladder cancer
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Fuzhou, FujianAges 18–85 - NCT06916494RecruitingPhase 1
Rutin plus immunotherapy and chemo before bladder cancer surgery
This trial tests a combination of the natural supplement rutin, an immunotherapy (tislelizumab), and two chemotherapy drugs (gemcitabine and cisplatin) before surgery for bladder cancer that didn't respond to initial chemo. It aims to see if this mix can shrink tumors better.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT05739968Recruiting
Active living program for early bladder cancer patients with their own bladder
This trial tests whether a structured “active-living” program (helping you be more active in daily life) improves outcomes for people newly diagnosed with operable early bladder cancer. It may help with overall health and quality of life while you receive standard bladder cancer care without removing your bladder.
TaipeiAges Any age - NCT05779631Recruiting
MRI test to better stage suspected bladder cancer
This study uses a special MRI scan (mpMRI) to figure out how far suspected muscle-invasive bladder cancer has spread, using a new local staging approach. If the results are accurate, it may help doctors plan the most appropriate curative treatment sooner.
's-HertogenboschAges 18 years+ - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT06092450Recruiting
Using AI scans to predict bladder cancer treatment results
This trial uses an artificial intelligence model to analyze CT scans taken before bladder removal surgery. The goal is to see if the AI can predict outcomes for patients with muscle-invasive bladder cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT06341400RecruitingPhase 1/Phase 2
Combination drug treatment before bladder cancer surgery
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06417190RecruitingPhase 2
Bladder preservation trial for muscle-invasive bladder cancer with variant histology
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06511648RecruitingPhase 2
Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Clermont-FerrandAges 18 years+ - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscle invasive bladder cancer (mibc)?
- Yes. Clin2 currently lists 35 recruiting muscle invasive bladder cancer (mibc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle invasive bladder cancer (mibc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle invasive bladder cancer (mibc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Muscle Invasive Bladder Cancer
- High Risk Non-muscle Invasive Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Muscle-Invasive Bladder Carcinoma
- Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Neoplasms
- Non-Muscle Invasive Bladder Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.